TGNA:FRA
Transgene SA
€0.67
arrow_downward
-0.15%(-0.00100) 1 دن
13 اکتوبر, 10:00:00 PM GMT +2 · EUR
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoTGNA کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
€0.67
اعلی
€0.67
کم
€0.67
مارکیٹ کی سرمایہ کاری
19.22 کروڑ
اوسط والیوم
0.00
والیوم
0.00
52 ہفتے میں اعلی
€1.48
52 ہفتے کا کم
€0.60
EPS
-€0.17
ملازمین کی تعداد
152
کھولیں
€0.67
اعلی
€0.67
کم
€0.67
مارکیٹ کی سرمایہ کاری
19.22 کروڑ
اوسط والیوم
0.00
والیوم
0.00
52 ہفتے میں اعلی
€1.48
52 ہفتے کا کم
€0.60
EPS
-€0.17
ملازمین کی تعداد
152
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
The Globe and Mail
·
58 منٹ پہلے
Kaplan Fox Encourages Fluence Energy, Inc. (NASDAQ: FLNC) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 27, 2026
TradingView
·
1 گھنٹہ پہلے
S&P 500 Ends Flat, While Nasdaq Drops As Memory Chipmakers Sell Off — BAC, GME, SPCX, ARM, QCOM In Focus
MarketBeat
·
1 گھنٹہ پہلے
Insider Selling: Citi Trends (NASDAQ:CTRN) VP Sells $25,285.00 in Stock
Investor's Business Daily
·
16 منٹ پہلے
Dow Jones Futures: Stock Market Holds Up As Meta, AMD Lead Buys; ASML, CPI Inflation Due
پروفائل
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA کے بارے میں